WHO《母亲和儿童的重点药物目录》的发布与启示  

Release and Enlightenment of WHO "Priority Medicines for Mothers and Children"

作　　者：肖爱丽[1] 井春梅[1] 

机构地区：[1]国家食品药品监督管理局药品评价中心,北京市100045

出　　处：《中国药房》2011年第40期3748-3752,共5页China Pharmacy

摘　　要：目的:为我国尽早颁布实施母亲和儿童用药相关目录提供证据支持。方法:查阅大量国内、外文献资料,研究世界卫生组织(WHO)《母亲和儿童的重点药物目录》发布背景、原则以及内容,对我国母婴健康状况、儿童用药状况进行分析。结果与结论:我国母婴健康状况面临严峻挑战,儿童用药严重缺乏,我国应该借鉴WHO制定各种基本药物目录的标准与方法,结合国情,根据疾病负担,依据循证医学原则和药物经济学原理,制定适合我国流行病和临床需求的《儿童基本药物目录》或《母亲和儿童的重点药物目录》。OBJECTIVE： To provide evidence support for the promulgation and implementation of relevant list in China as soon as possible. METHODS： By searching a large number of domestic and foreign literatures, researching WHO ＂Priority Medicines for Mothers and Children＂ in terms of the release background, principles and content, etc, the situation of maternal and children health and drug use in children were analyzed in China. RESULTS ＆ CONCLUSIONS： Maternal and children health in China is facing severe challenges, with a serious lack of medicines for children. Our country should refer the formulating standards and methods of various WHO essential drug lists, combined with national conditions, depended on the disease burden, based on the ev- idence-based medicine and pharmacoeconomics, to develop ＂Essential Medicines List for Children＂ or ＂Priority Medicines for Mothers and Children＂ which adapt to China＇s epidemiological and clinical needs.

关 键 词：母亲和儿童的重点药物目录 发布 启示 

分 类 号：R95[医药卫生—药学]